Targeting allosteric pockets of SARS-CoV-2 main protease M^pro

Area of Science:

• Virology
• Drug Discovery
• Computational Chemistry

Background:

• Repurposing existing antiviral drugs is a key strategy for combating COVID-19.
• The SARS-CoV-2 main protease (Mpro) is crucial for viral replication and a significant drug target.
• Challenges in Mpro-targeted therapy include its conformational flexibility and potential for mutations.

Purpose of the Study:

• To identify effective antiviral drug combinations for targeting the SARS-CoV-2 Mpro.
• To explore the potential of Elbasvir, Glecaprevir, and Ritonavir in combination therapy.
• To provide a basis for further experimental validation and pharmacophore design.

Main Methods:

• Molecular docking simulations were employed to assess drug-target interactions.
• Extensive molecular dynamics (MD) simulations were performed to analyze Mpro's conformational behavior.
• The study focused on interactions within both catalytic and allosteric pockets of Mpro.

Main Results:

• The combination of Elbasvir, Glecaprevir, and Ritonavir demonstrated potential efficacy against Mpro.
• Computational analysis supported the viability of this drug combination for COVID-19 treatment.
• Drug interactions within Mpro's active and allosteric sites were evaluated.

Conclusions:

• Elbasvir, Glecaprevir, and Ritonavir represent a promising combination for repurposing against SARS-CoV-2.
• The study provides a strong foundation for experimental drug testing and development.
• Targeting Mpro with specific drug combinations offers a viable therapeutic strategy for COVID-19.